EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Spectrum of KRAS variants in primary lung mucinous adenocarcinoma: implications for diagnosis, testing, and therapy

Arkar Htoo, Renuka Malenie, Juan Xing

Journal of the American Society of Cytopathology · 2026

DOI: 10.1016/j.jasc.2026.01.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Cytopathology, 2026. Verfasst von Arkar Htoo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Adenocarcinoma, Mucinous, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Primary lung mucinous adenocarcinoma (PLMAC) frequently harbors KRAS mutations; however, the distribution of KRAS variants in PLMAC remains under-characterized. This study aimed to investigate the KRAS mutational profile in PLMAC. MATERIALS AND METHODS: Cases of PLMAC (2018-2022) and primary lung nonmucinous adenocarcinomas (PLNMAC) (Oct-Dec 2022) were identified from pathology archives. Molecular testing was performed using a next-generation sequencing lung cancer hotspot gene panel. Specimen types, molecular results, demographic data, and smoking status were recorded. Statistical significance was assessed using an online Z-score calculator. RESULTS: A total of 117 PLMAC and 185 PLNMAC cases were identified. KRAS mutations were more common in PLMAC (62/86, 72%) compared to PLNMAC (61/154, 40%). In PLMAC, the most common KRAS variants were G12V (39%), followed by G12D (32%), while G12C was found in 19%. In PLNMAC, G12C was the predominant variant (47%). Among 27 (23%) never-smoking PLMAC patients, 17 were tested, and 12 (71%) harbored KRAS mutations-all non-G12C. Among 26 (14%) never-smoking PLNMAC patients, 20 were tested, and only one had a KRAS mutation, which was G12C. CONCLUSIONS: In our cohort, KRAS mutations were more prevalent in PLMAC than PLNMAC (72% vs. 40%, P < 0.05). However, the KRAS G12C variant was significantly less frequent in PLMAC compared to PLNMAC (19% vs. 47%, P < 0.05), suggesting that patients with PLMAC are less likely to benefit from KRAS G12C-targeted therapy. These findings underscore the importance of comprehensive KRAS genotyping and highlight the need for developing additional KRAS variant-targeted therapy for patients with PLMAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Adenocarcinoma, MucinousLung NeoplasmsAdenocarcinoma of LungHumansFemaleMutationMiddle AgedMaleAgedAged, 80 and overAdultHigh-Throughput Nucleotide SequencingDNA Mutational Analysis

Stichwörter der Autor:innen

G12C variantKRAS mutationMolecular testingMucinous adenocarcinomaNonsmall cell lung cancerTargeted therapy

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Pathology, Cleveland Clinic, Cleveland, Ohio.
  • Department of Pathology, Cleveland Clinic, Cleveland, Ohio. Electronic address: xingj@ccf.org.

Zitieren

APA

Htoo, A., Malenie, R., & Xing, J. (2026). Spectrum of KRAS variants in primary lung mucinous adenocarcinoma: implications for diagnosis, testing, and therapy. Journal of the American Society of Cytopathology. https://doi.org/10.1016/j.jasc.2026.01.002

Vancouver

Htoo A, Malenie R, Xing J. Spectrum of KRAS variants in primary lung mucinous adenocarcinoma: implications for diagnosis, testing, and therapy. Journal of the American Society of Cytopathology. 2026. doi:10.1016/j.jasc.2026.01.002

BibTeX
@article{Htoo2026,
  author = {Htoo, Arkar and Malenie, Renuka and Xing, Juan},
  title = {Spectrum of KRAS variants in primary lung mucinous adenocarcinoma: implications for diagnosis, testing, and therapy},
  journal = {Journal of the American Society of Cytopathology},
  year = {2026},
  doi = {10.1016/j.jasc.2026.01.002}
}
Kostenlos starten →